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Age-related macular degeneration (AMD) remains a major cause of blindness, with 29 
dysfunction and loss of retinal pigment epithelium (RPE) central to disease 30 
progression. We engineered an RPE patch comprising a fully differentiated, human 31 
embryonic stem cell (hESC)–derived RPE monolayer on a coated, synthetic 32 
basement membrane. We delivered the patch, using a purpose-designed 33 
microsurgical tool, into the subretinal space of one eye in each of two patients with 34 
severe exudative AMD. Primary endpoints were incidence and severity of adverse 35 
events and proportion of subjects with improved best-corrected visual acuity of 15 36 
letters or more.  We report successful delivery and survival of the RPE patch by 37 
biomicroscopy and optical [AU: OK?] coherence tomography, and a visual acuity 38 
gain of 29 and 21 letters in the two patients, respectively, over 12 months. Only local 39 
immunosuppression was used long-term. We also present preclinical, surgical, cell 40 
safety and tumorigenicity studies leading to trial approval. This work supports the 41 
feasibility and safety of hESC-RPE patch transplantation as a regenerative strategy 42 
for AMD. 43 
 44 
INTRODUCTION 45 
Human ESCs represent a promising source for cellular replacement therapies owing to 46 
their availability, pluripotency, and unlimited self-renewal capacity. However, they also 47 
carry risks of neoplastic change, uncontrolled proliferation, and differentiation to 48 
inappropriate cell types1, 2. The eye is advantageous in investigating hESC-based cell 49 
therapy, as it is accessible and confined, and the transplanted cells can be monitored 50 
directly in vivo, with the possibility of being removed or destroyed if there is evidence of 51 
neoplastic change3, 4. Furthermore, long-term immunosuppression can be delivered locally.  52 
 53 
Late AMD is characterized by irreversible cell loss, initially of RPE cells and subsequently 54 
of neuroretinal and choroidal cells5, and thus may be amenable to hESC-based cell 55 
therapy4. The disease process includes damage to the RPE’s specialized basement 56 
membrane, Bruch’s membrane5. Currently, treatments exist only for the exudative or ‘wet’ 57 
form of AMD. These treatments rely on angiogenesis inhibitors 6 or indirect transplantation 58 





However, the former treatment only suppresses the disease, requiring long-term 62 
repeat delivery, and the latter, although restoring the macular anatomy, does not prevent 63 
disease recurrence. It is possible that hESC-RPE patch may alter the natural history of the 64 
disease as the cells are zero years old, rather than the 60 plus years of the patients, and it 65 
does not contain predisposition to develop AMD that the host cells have already manifest, 66 
however, only further investigations will address this. There is no treatment for atrophic 67 
‘dry’ AMD, which is characterized by RPE loss and progressive neuroretinal cellular 68 
dysfunction.  69 
Suspensions of hESC-derived RPE (hESC-RPE) cells have been transplanted in 70 
human subjects with dry AMD and Stargardt’s disease, but the extent of cell survival and 71 
restoration of vision remains ambiguous 8. A recent, single-patient report described 72 
transplantation of an autologous induced pluripotent stem cell (iPSC)–derived RPE patch 73 
on its own secreted basement membrane29. The iPSC-RPE survived with maintenance, but 74 
no improvement, of visual acuity at 12 months. We developed a therapeutic, biocompatible 75 
hESC-RPE monolayer on a coated synthetic membrane, herein termed a ‘patch’, for 76 
transplantation in wet and early-stage dry AMD. The choice of membrane material and its 77 
preparation, including the human vitronectin coating, has not been described previously to 78 
our knowledge. In contrast to RPE suspensions, cells on the patch are delivered fully 79 
differentiated, polarized, and with the tight junction barrier formed, that is, in a form close to 80 
their native configuration. The synthetic membrane allows the patch to be handled easily 81 
and robustly. The main disadvantage of the patch is that it requires a purpose-built delivery 82 
tool and a more complicated surgery compared to cell suspensions, and the use of hESCs 83 
may require immunosuppression, unlike an autologous cell source. Our delivery tool 84 
(Supplementary figure 1) confers the benefit of protecting the patch within the tip, thereby 85 
minimizing cell loss, cell distribution within the eye, and physical damage to the RPE 86 
monolayer.  87 
 88 
The clinical trial was designed as a phase 1, open-label, safety and feasibility study 89 
of implantation of a hESC-RPE patch in subjects with acute wet AMD and recent rapid 90 
vision decline. For safety reasons and to obtain an early efficacy signal, the initial clinical 91 
trial involved patients with severe wet AMD only, although we aim to study the RPE patch 92 
in early dry AMD as well. We reported three serious adverse events to the regulator. These 93 
were exposure of the suture of the fluocinolone implant used for immunosuppression, a 94 
retinal detachment, and worsening of diabetes following oral prednisolone. All three 95 
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incidents required readmission to the hospital, with the first two incidents requiring further 96 
surgery and the third being treated medically. The three incidents were treated 97 
successfully. Both patients achieved an improvement in vision of more than 15 letters, 98 
which was sustained for 12 months.  99 
 100 
RESULTS 101 
Engineering an RPE patch 102 
Our protocol for manufacturing a clinical-grade RPE patch is summarized in Figure 1. RPE 103 
cells were differentiated from the SHEF-1.3 hESC line, which had been derived from the 104 
SHEF1 hESC line. We used a spontaneous differentiation method 9, an approach that has 105 
been described earlier by others and has been applied to primate 10 and human 11, 12 106 
ESCs. Spontaneous differentiation limits the need for additional factors, thus complying 107 
with good manufacturing practice (GMP) guidelines, and with clear advantages over 108 
vector-driven methods in terms of safety and stability of the final RPE. Our differentiation 109 
protocol differs from another similar protocol 9 in that we used Essential 8 medium rather 110 
than human feeder cells during expansion and the early phase of differentiation to avoid 111 
exposure to another cell type and to fulfill GMP guidance. While several methods are used 112 
to produce hESC-RPE 10, 12, 13, 14, because of epigenetic variation from the earliest stages 113 
after derivation of hESCs, no method is universally effective 14, 15. With our protocol, 20–114 
30% of hESC colonies differentiated to RPE (data not shown), which is similar to that of 115 
other spontaneous methods 10, 12 but less efficient than some augmented methods 14-16.  116 
 117 
Subsequent RPE characterization used immunocytochemistry, electron microscopy, 118 
pigment-epithelium-derived factor (PEDF) secretion profile testing, and a functional 119 
phagocytosis assay (Fig. 2d). During manufacturing, in-process testing, including in situ 120 
hybridization with a specific oligonucleotide probe for LIN28A mRNA11, was undertaken to 121 
detect hESC impurity at the single-cell level. Differentiated RPE was discarded if any 122 
LIN28A-positive cells were detected. The hESC-RPE cells were seeded at confluence onto 123 
a human-vitronectin-coated polyester membrane. A 6 × 3 mm (17 mm2) therapeutic 124 
element with ~100,000 cells (PF-05206388 in the regulatory documentation) was cut to 125 
size with a purpose-built punch and loaded into a sealed transport container (Fig. 1). 126 
Immediately prior to release for human transplantation, the cell layer was recharacterized 127 
as RPE according to a visual inspection release test encompassing cell dose, cell identity, 128 




Mouse teratoma and in vitro cell-spiking studies 131 
The literature suggests that adult human RPE cells17, terminally differentiated hESC-132 
RPE18, and spontaneously immortalized RPE cells19 are non-proliferative cell types and 133 
appear to lack the potential to form teratomas. We tested tumorigenicity in NIH III nude 134 
mice. Cell suspensions were used as the mouse eye is too small to administer a patch. 135 
Two initial studies conducted with undifferentiated hESCs showed that teratomas could 136 
form. In these studies, cell suspensions were injected subretinally, intra-muscularly and 137 
subcutaneously, with mice followed for 26 weeks. Subsequently, we studied the 138 
tumorigenicity of hESC-RPE cells under good laboratory practice (GLP) conditions, 139 
including a positive control group injected with undifferentiated hESCs. Given our finding 140 
that undifferentiated hESCs formed teratomas, we conducted in vitro cell-spiking studies to 141 
examine whether hESCs survive the RPE manufacturing process and culture-seeding 142 
conditions.  143 
 144 
In the first study, injection of 4.5–8.8 × 104 undifferentiated hESCs into the subretinal 145 
space of NIH III mice resulted in localized neoplastic formation in almost half the males 146 
injected (12/30) but in very few females (2/30). The tumors showed evidence of 147 
pluripotency and appeared to be composed of mesenchymal and epithelial lineages (data 148 
not shown). 149 
 150 
In the second study of undifferentiated hESCs, neoplastic masses were observed in 151 
the injected eye of 12/15 female and 5/5 male mice after cell administration into the 152 
subretinal space. Teratomas were observed microscopically in the thigh of all female mice 153 
that received 3.6 × 104 or 8.23 × 105 undifferentiated hESCs in BD Matrigel by the 154 
intramuscular route, and in the left flank of 2/5 and 1/11 female mice that received 3.6 × 155 
104 or 8.23 × 105 undifferentiated hESCs in BD Matrigel, respectively, by the subcutaneous 156 
route. Masses were composed of structures derived from all embryonic germ layers (data 157 
not shown).  158 
 159 
In the third study, conducted with cells manufactured under GLP conditions, 160 
suspensions of hESC-RPE cells, or of undifferentiated hESCs as a positive tumorigenic 161 
control, were injected subretinally in NIH III mice. In a total of 80 mice injected with 162 
suspensions of hESC-RPE cells, no teratomas were detected (Fig 3B). Pigmented hESC-163 
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RPE cells were observed lining the surface of the retina or lens in the injected eyes of 164 
some mice given 6.04 x 104 hESC-RPE cells (Fig.3 E1, E2 and E3 at 26 weeks (Fig.3E1). 165 
No premature death was associated with the injections.  166 
 167 
In the same study, administration of undifferentiated hESCs was associated with 168 
ocular teratoma formation in four males and five females given 4.28 x 104 cells, all of which 169 
were prematurely euthanized (between days 46–62), and in a single male given 4.51 × 103 170 
cells, which survived to the 26 week end point of the experiments (Fig 3C). In addition, 171 
mesenchymal tumors classified as “Not Otherwise Specified” were present in two males 172 
given 4.28 × 104 undifferentiated hESCs (Fig 3D) and perilenticular mesenchymal 173 
hyperplasia in animals of both sexes given 4.51 × 103 cells or 4.28 × 104 cells. All tumors 174 
were composed of human cells, as confirmed by immunohistochemistry using an anti-175 
human mitochondrial marker (data not shown). Eyes injected with undifferentiated hESCs 176 
also exhibited an increase in the incidence and severity of non-proliferative changes, 177 
including lenticular degeneration, posterior synechiae of the iris, and retinal detachment 178 
(data not shown). Transplantation of either differentiated or undifferentiated hESCs did not 179 
affect body weight. 180 
 181 
Given the tumor formation observed with undifferentiated hESCs, we aimed to 182 
determine whether hESC-RPE derived from SHEF-1.3 hESC contained any residual 183 
pluripotent cells or could support the survival of pluripotent cells, as this would constitute a 184 
teratoma risk.  Immunostaining and flow cytometric analysis of cells expressing the 185 
pluripotency marker Tra-1-60 (Abcam 16288, Cambridge, UK) detected no undifferentiated 186 
hESCs in dissociated RPE foci prior to the expansion phase or at 6 to 8 weeks after 187 
seeding at the end of the expansion phase (Supplementary figure 2). We spiked 188 
undifferentiated hESCs into the RPE at 1, 10, 20 or 50% of total cells at the start of the 189 
expansion phase (see online methods). This did not affect the quality of the resulting 6-to-190 
8-week-old cultures at the end of the expansion phase, which showed cobblestone 191 
morphology and pigmentation, and stained strongly for PMEL17 (an RPE marker that 192 
indicates the presence of premelanosomes). By 2 d post-spiking, viable Tra-1-60-positive 193 
cells were no longer detectable by flow cytometry (data not shown). This finding was 194 
supported by propidium iodide staining, which showed that ~96% of hESCs died when 195 
dissociated and seeded in the same manner as RPE prepared for expansion 196 
(Supplementary figure 3). The cells that survived in some experiments did not have hESC-197 
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like morphology and failed to stain for Tra-1-60 or the proliferation marker Ki67, suggesting 198 
that they had differentiated or senesced (Supplementary figure 3 D&E).  199 
 200 
Pig single-dose studies 201 
Studies of surgical feasibility and safety of delivery of the RPE patch as well as studies of 202 
local and systemic biodistribution and toxicity were carried out in pigs. Human and pig eyes 203 
are similar in size, which allowed for administration of the full-size patch. Two studies were 204 
performed; the second used the same clinical surgical technique as in the human clinical 205 
trial. Biodistribution of hESC-RPE cells was evaluated in more than ten sites using qPCR 206 
detection of multiple human cell markers.  207 
 208 
 In the first pig study, patch delivery was successful in all 20 animals, as assessed by 209 
intraoperative observation of the patch under the neural retina and histological sections 210 
showing the patch in the subretinal space (figure 3 H & I). No retinal detachments were 211 
noted in any animal. We found surviving human cells by light microscopy at 2 h, 2 d, and 1, 212 
2, 4, and 6 weeks after implantation (RPE patch: n = 12; control patch without cells: n = 8; 213 
figure 3 H-K). Human [AU: OK?] cell survival was demonstrated despite 214 
immunosuppression having been limited to the peri-operative period using oral 215 
prednisolone. Surviving cells remained pigmented (Fig. 3 J), expressed RPE-specific cell 216 
markers, showed no proliferation activity, and did not migrate away from the membrane 217 
(data not shown). [AU: Clarify: ‘Human’ or ‘Human or pig’?] Pig photoreceptor survival 218 
above the patch was observed only in animals that received an RPE patch, as assessed by 219 
histology (Fig. 3H). The control membrane without cells did not pig photoreceptor survival 220 
(Fig. 3I). Microscopically, retinal architecture was intact in most animals receiving human 221 
cells. Macrophages were seen and appeared to have phagocytosed some transplanted 222 
RPE cells to form large pigmented cells (data not shown). Lymphocytic infiltrate was not 223 
observed except in 2 animals at 2 and 6 weeks. Animals that received the control 224 
membrane also had macrophage infiltrates but no lymphocytic response (data not shown). 225 
These results demonstrated that patch transplantation with hESC-RPE survival was 226 
surgically feasible without significant safety issues.  227 
 228 
The second pig study differed from the first in that we used the purpose-built 229 
surgical tool, which  has a protective cradle at the tip from which the patch is mechanically 230 
pushed out when the tip is in the subretinal space (Supplementary figure 1). The study was 231 
8 
 
undertaken under GLP conditions, a standardized set of requirements to ensure quality 232 
and systematic management of the experiment. In this case, it dictated standards for the 233 
operating and animal facilities and for the personnel who ran the trial, and defined the 234 
conditions and requirements for the keeping and monitoring of animals in the study, 235 
including the feeding regimen. Correct surgical delivery of ten RPE patches and ten coated 236 
membranes without RPE was achieved in 20 pigs as assessed by clinical examination and 237 
histology (Figure 3 F & G). Good cell cover was observed at the 6-week time point in the 238 
ten animals that received RPE cells (Fig. 3F). Retinal detachment and rupture of the lens 239 
capsule were observed in one male and one female implanted with the patch. There was 240 
no evidence of weight loss or early death in any animal. At 6 months after implantation, no 241 
hESC-RPE cells were detected at the implantation site or elsewhere in H&E sections of the 242 
ten eyes receiving the RPE patch. Anti-human TRA-1-85 immunostaining of the operated 243 
eye and optic nerve from these animals was also negative. Microscopic findings of chronic 244 
inflammation were seen restricted to the subretinal implantation site, at 6 months in the 245 
implanted (left) eye of all animals, and were consistent with the intraocular surgical 246 
implantation procedure. The microscopic findings included fibrosis, osseous metaplasia, 247 
and small numbers of macrophages and multinucleate giant cells (data not shown). 248 
Atrophy of the photoreceptor layer in overlying retina was also present (data not shown). 249 
Findings were of similar incidence and severity in both control and cell-treated animals. No 250 
positive amplification of any human-specific genes was observed in adrenal, bone marrow 251 
(rib and femur), brain, heart, kidneys, liver, lungs, lymph nodes, optic nerve, spleen, or 252 
thymus, which were evaluated by qPCR, indicating that the cells did not appear to migrate 253 
or survive away from the site of implantation. The second pig study confirmed the surgical 254 
feasibility and reliability of the delivery tool and the lack of systemic or local distribution of 255 
the hESC-RPE cells. 256 
 257 
Clinical trial  258 
Regulatory permission was granted for a phase I trial on the basis of the preclinical studies 259 
reported in this article, and published data on the hESC-RPE monolayer9 (Clinical 260 
Trials.gov: NCT01691261). Permission was granted for ten patients, and we report the 261 
primary and secondary outcomes from the first two (Figs 4, 5, 6 and 7). In addition to 262 
safety, the trial investigated whether the synthetic membrane would facilitate mechanical 263 
delivery of the RPE monolayer, whether the transplanted cells could be sustained long-264 
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term with local immunosuppression only, and whether early signals of potential efficacy 265 
were evident.  266 
  267 
Using the surgical delivery tool, we placed one RPE patch in the subretinal space, 268 
under the fovea, in the affected eye of each patient. Correct placement was confirmed in 269 
both patients by stereo-biomicroscopy, fundus photography, and spectral domain optical 270 
coherence tomography (SD-OCT) (Figs. 4b1, b2 and 5b1, b2).  271 
 272 
In patient 1, OCT and native-level autofluorescence immediately after surgery 273 
showed a ‘double thickness’ of RPE in one area nasal to the fovea, indicating overlap of 274 
native RPE and the patch (Figs. 4b, c, d). In all other areas of patient 1, and in all areas of 275 
patient 2, a single layer of RPE on OCT suggested there was no residual native RPE over 276 
the patch (figures 4b1 and 5b1). In both patients, hESC–RPE remained present over the 277 
full area of the patch at 12 months as evidenced by dark pigmented cells covering the 278 
patch, although unevenly, on fundus photography and a hyper-reflective monolayer on the 279 
patch seen by SD-OCT (figures 4a1,b1, 5a1, b1 and 6a and b). In both patients, the 280 
patches showed uneven autofluorescence (figures 4e3 and 5e3), which suggests 281 
functioning RPE phagocytosis 20, 21. Also, visible in both patients were darker, pigmented 282 
areas continuous with the patch, which may represent RPE cell migration off the patch onto 283 
adjacent RPE-deficient areas. These areas spread from the patch edge outward over the 284 
first 6 months after surgery before stabilization (Fig. 6 a and b). The areas were contiguous 285 
with the patch RPE signal on OCT and were absent in areas where the native RPE layer 286 
persisted. There was no evidence of neoplastic transformation either on regular review of 287 
the fundus by an ocular oncologist or by serial ocular ultrasound. 288 
 289 
In addition to RPE survival, we studied visual recovery. All measurements of visual 290 
acuity were made once before surgery and once at 12 months after surgery, and testing 291 
was always carried out by an independent qualified observer.  The Early Treatment 292 
Diabetic Retinopathy Study (ETDRS) letter chart was used to define best corrected visual 293 
acuity (BCVA—vision with an optometrist-determined best glasses-corrected vision), which 294 
improved from 10 to 39 and from 8 to 29 letters, over 12 months in patients 1 and 2, 295 
respectively (Figs 7a and 7c). Microperimetry, a test of perception of microlocalized light 296 
stimuli, showed visual fixation at the center of the patch and vision over the patch in both 297 
patients (Figs. 4b1 and 5b1). Figures 4b1 and 5b1 show sample areas of visual sensitivity 298 
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localized totally within the patch. Over 12 months, reading speed improved from 1.7 to 82.8 299 
and from 0 to 47.8 words/min in patients 1 and 2, respectively, by Minnesota MN Read 300 
(figs 7b and 7d), an improvement and final level not found in the Submacular Surgery Trial 301 
22. Pelli–Robson contrast sensitivity scores (Log) improved from 0.45 to 1.35 in patient 1, 302 
and 0 to 1.05 in patient 2, over 12 months. At each point that showed microperimetry 303 
sensitivity over hESC-RPE, we observed choroidal filling by angiography (Figs. 4e1, 4e2, 304 
5e1 and 5e2); RPE-autofluorescence (Figs. 4e3 and 5e3; and presence of the ellipsoid 305 
layer (indicative of preserved photoreceptors) by SD-OCT (Figs. 4c1, 4c2, 5c1 and 5c2). 306 
We note that it was not possible to ascertain whether the ellipsoid zone was present pre-307 
operatively, owing to the poor detail in the pre-operative OCT scans (Figs. 4a2 and 5a2). 308 
Rtx1 Adaptive optics camera images showed survival of cone photoreceptors in the areas 309 
corresponding to areas of sensitivity on microperimetry (Figures 4d1, 4d2, 5d1 and 5d2).  310 
 311 
We reported three serious adverse events that were unrelated to the RPE patch. 312 
The first was exposure of the suture of the fluocinolone implant in patient 1, which required 313 
conjunctival revision surgery. The other two, both in patient 2, were a worsening of 314 
diabetes following oral prednisolone, which was treated medically, and a retinal 315 
detachment. The retinal detachment was an asymptomatic, infero-temporal, proliferative 316 
vitreoretinopathy (PVR)-associated traction retinal detachment under silicone, which did 317 
not extend past the inferior arcade and thus did not affect the implant. It was observed at 318 
the 8-week follow-up, with the retina having been completely attached at the 4-week check.  319 
It was treated with a single surgery with peeling of the PVR membranes, inferior 320 
retinectomy of the peripheral retina (180 degrees), and laser to the retinectomy edge. The 321 
silicone oil was retained.  The retina was attached at the end of the surgery and has 322 
remained attached after subsequent surgery to remove the silicone oil. There was a 323 
residual epiretinal band over the posterior pole with some focal macular traction (figures 324 
5b1 and 6b.), which was not treated. 325 
 326 
Ocular pressures were never raised in either patient. No changes of concern were 327 
noted in the liver and renal function tests and by liver ultrasound in either patient. On full-328 
field electro-retinography (ERG) recording, there was evidence of a mild but consistent 329 
reduction in photoreceptor function at 6 months in both patients with additional consequent 330 
Electro-oculography (EOG) reduction (in the operated eyes). The reduction in 331 





The results presented here provide an early indication of the safety and feasibility of 335 
manufacturing an hESC-RPE monolayer on a synthetic basement membrane and 336 
delivering the patch into the subretinal space as a potential treatment for AMD. Our data 337 
suggest early efficacy, stability, and safety of the RPE patch for up to 12 months in two 338 
patients with severe vision loss from very severe wet AMD.  339 
 340 
hESC-RPE on a membrane shows optimized differentiation, polarization, viability, 341 
and maturation of the monolayer at the time of delivery that contrasts favorably with 342 
delivery of cell suspensions, where the cells are necessarily not in a monolayer and 343 
thereby not polarized or fully differentiated. Proper orientation is readily confirmed by the 344 
color difference between the white membrane and the pigmented RPE. Cells delivered in 345 
suspension may be lost due to reflux through the retinotomy, with potential vitreous 346 
seeding, and the cells undergo shear stress and damage when ejected through the 347 
delivery cannula23. Furthermore, cells in suspension are required to adhere to and form a 348 
monolayer on a damaged native Bruch’s membrane, which leads to poorer cell survival 349 
and widespread apoptosis24. Previous work showed poor differentiation using suspensions 350 
and that RPE monolayers on membranes appear superior25.  351 
 352 
Therapeutic human RPE patch transplantation has been reported using a harvested 353 
autologous RPE–Bruch’s membrane–choroid patch from the same eye 26, 27, 28 and an 354 
induced pluripotent stem cell (iPSC)-derived RPE patch29. The main advantages of our 355 
system over these were mechanical ease of handling due to the rigidity of the synthetic 356 
membrane. The tool we developed also allowed consistent patch delivery with a small 357 
localized retinal detachment over the macula, whereas with the intraoperative harvested 358 
autologous technique, half of the entire retina must be reflected to ensure consistent 359 
delivery without RPE damage30, 31. The availability of an off-the-shelf patch is especially 360 
advantageous and critical in cases of severe wet AMD with sudden vision loss, as 361 
described in this study. Treatment is required rapidly32, and an autologous iPSC patch 362 
could not be prepared in a suitable time frame for transplantation. The main disadvantage 363 
of our technology is the need for immunosuppression, although for the two cases reported 364 
here we have demonstrated that only local immunosuppression is necessary for long-term 365 




We present key preclinical safety and tumorigenicity studies that supported 368 
regulatory approval of our clinical study. The GLP study of tumorigenicity in NIH III mice 369 
showed that the hESC-RPE was not associated with tumor formation or other notable 370 
proliferative changes. Injected hESC-RPE cells survived for the full 26 weeks in some 371 
animals. Transplantation of undifferentiated hESCs under the same conditions was 372 
associated with teratoma formation as well as unclassified mesenchymal tumors, peri-373 
lenticular mesenchymal hyperplasia, and an increase in the incidence and severity of 374 
degenerative changes in the treated eye (fig 3C and 3D).   375 
 376 
Owing to tumor formation by undifferentiated hESCs, the major safety concern 377 
became the potential for survival and persistence of undifferentiated hESCs through the 378 
manufacturing process. In-process testing for undifferentiated cells is essential in the 379 
manufacture of any cell product from pluripotent cells for human transplantation. Spiking 380 
studies and single-cell labeling studies demonstrated no detectable undifferentiated cells in 381 
the final product. Even when we contaminated primary foci of hESC-RPE cells with up to 382 
50% undifferentiated hESCs, no pluripotent hESC cells were present by the end of the 383 
expansion phase. Furthermore, hESCs were not viable when dissociated and seeded into 384 
RPE expansion conditions. Thus, we demonstrated that undifferentiated hESCs were not 385 
detectable at stage 4 of the production process, and that the RPE differentiation medium 386 
does not support the survival of hESCs.  387 
 388 
Our preclinical studies in pigs investigated surgical feasibility, biodistribution, and 389 
toxicity. We showed consistent facilitated mechanical delivery of the RPE patch in all 20 390 
pigs operated on in the GLP final study using our purpose-built tool. Implantation of the 391 
control membrane without cells led predictably to a foreign body reaction, but this was 392 
minimal when RPE cells covered the membrane.  The presence of RPE was also 393 
associated with persistence of the native photoreceptor layer and less retinal atrophy than 394 
membrane alone in both pig and clinical studies (Figures 3H, 3I, 4c1, 4c2, 4d1, 5c1, 5c2 395 
and 5d1). 396 
 397 
A qPCR analysis of systemic biodistribution in pigs at 26 weeks after implantation of 398 
one clinical-sized graft (~100,000 hESC-RPE cells) showed no evidence that cells 399 
migrated or survived away from the site of administration. The lack of distribution of the 400 
13 
 
cells is consistent with previous studies on ocular administration of RPE cells 19. This is 401 
also supported by our NIH III mouse study, in which teratomas from undifferentiated 402 
hESCs were found only in the eye, where the cells had been administered, and not in 403 
tissues distal to the site, suggesting that undifferentiated hESCs do not migrate or do not 404 
survive away from the site of implantation.  405 
 406 
In the GLP pig study with no immunosuppression, no definitive hESC-RPE cells 407 
were identified at 26 weeks, whereas persistent hESC-RPE cells were found at 6 weeks in 408 
the earlier pig studies in which some animals were immunosuppressed perioperatively), 409 
and at 26 weeks in the NIH III mouse teratoma studies (immune-deficient animals). 410 
Histology of the implanted patch at 6 weeks from animals in the first pig study showed 411 
persistence of human RPE and support of normal retinal architecture relative to animals 412 
receiving the membrane alone (Fig 7H and I.). Microscopic findings consistent with a 413 
localized chronic inflammatory reaction around the polyester membrane were present in 414 
animals from both groups in the GLP pig study at 6 months, in the absence of any RPE cell 415 
cover. There was no difference in the incidence or severity of the inflammatory reaction in 416 
either group.  417 
 418 
In the human clinical trial, the transplanted RPE patch survived, as demonstrated by 419 
a clear RPE signal on OCT for 12 months and the visible persistence of a pigmented 420 
cellular monolayer, although some of these cells may have been pigmented macrophages. 421 
There was evidence of early auto-fluorescence in both patients 1 and 2, suggesting that 422 
RPE phagocytosis has commenced 20, 21. The retina over the patch was thinned in patient 1 423 
but not in patient 2, which may reflect a difference in pre-operative disease or level of 424 
microtrauma from manipulation during surgery. It is possible that the decrease in central 425 
pigmentation in patient 1 represented cell loss from delayed rejection. Both patients 426 
retained features of normal architecture and visible areas of the ellipsoid zone. 427 
Furthermore, there was clear evidence of retinal function over the patch, as demonstrated 428 
by fixation microperimetry, which showed focal sensitivity, and increased visual acuity and 429 
reading speed, all of which were sustained or improved over the 12 months of follow-up. 430 
However, in the absence of a control, proving the improvement was due to the transplant is 431 
not possible. The improvement in reading exceeded that of similar cases in the submacular 432 
surgery trial 22. Visual function remained variable across the transplanted area, with poor 433 
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visual function and thinning centrally in patient 1, which we feel may reflect intra-operative 434 
surgical trauma.  435 
 436 
While histological evidence of hESC-RPE survival is not possible, the extensive 437 
number of structural and functional features discussed above support the conclusion that 438 
the hESC-RPE survived. Furthermore, the presence of transplanted hESC-RPE cells 439 
immediately adjacent to the neuroretina suggest that they are associated with retinal 440 
function over the patch. We did not intentionally remove the subretinal choroidal neo-441 
vascular membrane, but cannot exclude that it was removed inadvertently. Therefore, the 442 
effect of the original choroidal neovascular membrane on function remains ambiguous. 443 
However, the co-localization of choroidal perfusion, survival of hESC-RPE, retinal 444 
sensitivity, and presence of photoreceptors strongly support the conclusion that the visual 445 
improvement and stability was associated with the transplanted RPE patch.  446 
 447 
Retinal detachment was the most severe clinical complication seen. The GLP pig 448 
studies had two retinal detachments in 20 animals, which is similar to the rates reported for 449 
early human autologous transplantation and translocation surgeries33, 34. The retinal 450 
detachment in patient 2 of the clinical trial was likely a PVR-associated detachment that 451 
occurred between 4 and 8 weeks. It was treated with a single operation using standard 452 
techniques.  The retinal detachment did not extend far enough to reach the patch. 453 
However, despite the delivery of RPE cells on a patch and in a protected delivery device, 454 
both of which minimize the shedding of RPE cells into the vitreous, we cannot be certain 455 
that no hESC-RPE cells were released nor that they did not contribute to the risk of 456 
developing PVR. The true surgical risk can be assessed accurately only with a larger 457 
series of patients. 458 
 459 
 460 
In patient 1, there was an area of native RPE over the patch that was clearly 461 
delineated and separate from the large area over the patch where the native RPE was lost 462 
and only hESC-RPE was present (Figs 3 and 5). Notably, the patient fixated not over 463 
native RPE but over the RPE patch. Subjectively, patient 1 acknowledged that vision is 464 
improved relative to the pre-operative state and that she can see letters and read directly 465 
with the central vision; however, she described troublesome distortion, similar to that 466 
experienced by patients who have had previous retinal detachment or wet AMD. The 467 
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second patient described his vision as continuously improving but also being ‘dimmer’ than 468 
before the onset of the disease, which is consistent with his longer-standing disease at 469 
presentation and, likely, more damaged neuroretina.  470 
 471 
Reporting these first two cases at 12 months is valuable because the functional 472 
improvement, robust imaging data, lack of major safety concerns, and demonstration of 473 
sufficiency of local immunosuppression represent steps in support of hESC-based 474 
regenerative therapy for AMD and other diseases of the eye. We show that differentiation 475 
of hESCs into a therapeutic cell with delivery, survival and rescue of vision in very severe 476 
disease is feasible. Although 12 months is sufficient to begin to describe cell survival and 477 
clinical outcomes, it is early in terms of safety monitoring, especially for late teratoma 478 
formation. The patients will be followed for a total of 5 years after surgery. These two early 479 
cases are also instructive as they show an encouraging outcome despite very advanced 480 
disease, which increases the complexity of surgery and involves more-damaged 481 
neuroretina. Additionally, there was no evidence of recurrence of the neovascular 482 
membrane and no need to administer angiogenesis inhibitors to either patient at 12 483 
months, although with only two cases it is difficult to attribute this to the transplant. 484 
 485 
The role of immune privilege in the subretinal space remains ambiguous, and the 486 
immunological effect of the surgery and patch transplant is unknown. Stability of the 487 
transplant was achieved with immunosuppression consisting of perioperative oral 488 
prednisolone and long-term intraocular steroid implants. For patient 2, who has type II 489 
diabetes, there was a period of poor blood sugar control with the need to add insulin, due 490 
to the systemic steroid use. Given the concerns about long-term systemic 491 
immunosuppression, a notable finding of this study is that the transplanted hESC-RPE 492 
cells survived at least 12 months with only local immunosuppression. Although long-term, 493 
local immunosuppression can be provided in the eye without systemic side effects, the 494 
possibility of long-term ocular morbidity remains. In our two patients, there was no 495 
associated intraocular pressure rise or need for pressure-reducing medication.  496 
 497 
Stem-cell-based tissue transplantation is a potentially effective treatment strategy for 498 
neurodegenerative or other diseases with irreversible cell loss. Here we addressed 499 
challenges related to engineering, manufacturing and delivering a clinical-grade hESC-500 
RPE patch, leading to stabilization and improvement of vision for at least 12 months in two 501 
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subjects with severe vision loss from AMD. These findings support further investigation of 502 
our approach as an alternative treatment strategy for AMD. 503 
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Legends  673 
 674 
Figure 1 Generation of hESC-derived RPE for the manufacture of an advanced therapeutic 675 
medicinal product to treat AMD.  676 
This figure outlines the chronological process for manufacturing the RPE patch from SHEF-677 
1.3 hESCs. The first four rows show the stages of differentiation; the coating on the plastic-678 
ware for each step; the media used at each step; and the tests and checks performed at 679 
each step. The bottom row shows brightfield images illustrating each stage: [AU: add 680 
column to image and label each row] (i) hESC colonies expanded on recombinant 681 
human vitronectin (VTN-N). (ii) Spontaneously differentiated RPE cells appear as distinct 682 
pigmented foci.[AU: line is offset; does that mean E8 medium is used at the beginning 683 
of SHEF-1.3 differentiation? Please clarify ] (iii) These foci are manually dissected, 684 
dissociated, and filtered to achieve a pure single-cell type RPE population, which is seeded 685 
onto plates, where expanding RPE cells establish their classic pigmented, cobblestone 686 
morphology. (iv) Fully differentiated RPE seeded at confluence. [AU: add PET to text in 687 
figure as in v; deleted here] (v) A therapeutic ‘patch’ consisting of the RPE monolayer 688 
immobilized on the vitronectin-coated PET membrane that has been cut from the transwell. 689 
(vi) Following release tests the advanced therapeutic medicinal product is supplied to the 690 
surgical team in a custom-manufactured single-use sterile container in saline, where it is 691 
viable for up to 8 h. PMEL17, premelanosome marker 17; ICC, immunocytochemistry; ISH, 692 





Figure 2 Characterization of human hESC-derived RPE.  696 
 697 
(a) Confocal bright-field immunofluorescent micrographs depicting staining for typical 698 
regional RPE markers as part of the characterization of the monolayer as RPE (each 699 
represents a single experiment with no repeats). Scale bars, 25 µm. Predominantly apical 700 
PEDF and basal BEST1 expression confirms polarity of these cells. PMEL17 expression 701 
confirms presence of premelanosomes, and ZO1 expression allows easy identification of 702 
tight junctions. Absence of Ki67 confirms that cells are not proliferating. Other characteristic 703 
RPE markers (CRALBP, MITF, OTX2), crucial for melanogenesis and visual cycle, are also 704 
present. Immunocytochemistry was performed once on SHEF-1.3-derived RPE cells. 705 
BEST1, bestrophin 1; CRALBP, cellular retinyladehyde-binding protein; DAPI, diamidino-2-706 
phenylidole; MITF, microthalmia transcription factor; OTX2, orthodenticle homeobox 2; 707 
PEDF, pigment epithelium-derived factor; PMEL17, premelanosome protein 17; ZO1, 708 
zonula occludens 1. 709 
 710 
(b) Quantification of PEDF secretion in spent culture medium during late expansion phase, 711 
analyzed using an ELISA assay. The classical RPE PEDF secretion asymptote is visible 712 
from around 3 weeks onwards. Each different colored box represents a separate batch of 713 
tested cells. 714 
 715 
(c) Electron micrographs of RPE cells, illustrating the classical ultrastructure associated 716 
with normal RPE function including tight junctions (white arrows; i and iii), basal infoldings 717 
(black arrows; i and iv), apical microvilli (i–iii), and melanin granules (i–iii) revealing various 718 
stages of melanogenesis (ii; stage II/III, III melanosomes and stage IV mature 719 
melanosomes). Transmission electron microscopy was performed once on SHEF-1.3-720 
derived RPE cells. N, nucleus; AmV, apical microvilli. Images represent a single 721 
experiment with no repeats.   722 
 723 
(d) SHEF-1.3-derived RPE cells internalize photoreceptor outer segments (POS), 724 
demonstrating SHEF-1.3-derived RPE phagocytosis. The extent of phagocytosis was also 725 
examined after treatment of the SHEF-1.3 RPE with MERTK antibody (SHEF-1.3 RPE + 726 
blocker). Data shown are mean internalized POS ± s.e.m. (n = 3 biologically independent 727 
cell cultures in each group). Pre-incubation with MERTK antibody had a significant effect 728 
on the number of POS ingested by SHEF-1.3 RPE (P = 0.0000103075196107, two-tailed 729 
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Student’s t-test, This was a single experiment with no replication. Below the graph, 730 
confocal micrographs show the internalized POS with a green fluorescent marker (POS) in 731 
SHEF-1.3-derived RPE and its relative absence in SHEF-1.3 RPE with MERTK antibody 732 
(SHEF-1.3 RPE + blocker).  733 
 734 




Figure 3 Preclinical mouse teratoma and pig transplantation studies. 737 
 738 
NIH III immune-deficient mice preclinical teratoma studies.  739 
(a) Normal non-injected eye of a mouse (H&E).  740 
(b) 6-week-old animal injected with hESC-RPE (no teratomas or proliferation were 741 
observed in any animals from this group). Section taken 26 weeks after injection (H&E).  742 
(c) An example of teratoma formation in an animal injected with undifferentiated hESC. 743 
Section taken following euthanization of the animal prior to 26 weeks (H&E).   744 
(d) An example of a mesenchymal tumor NOS in an animal injected with undifferentiated 745 
hESC.  Section taken at termination of the animal prior to 26 weeks (H&E). 746 
(e, i) 6-week-old animal injected with hESC-RPE showing persistence of layers of 747 
pigmented cells at week 26. (e, ii) 6-week-old animal injected with hESC-RPE and 748 
examined with anti-human mitochondria IHC. Immunoreactivity for human mitochondria 749 
seen as a brown chromophore (black arrows), demonstrating that the cells represent 750 
implanted-hESC-derived RPE. (e, iii) 6-week-old animal injected with hESC-RPE and 751 
examined with an isotype control relative to section in e, ii with no positive staining (black 752 
arrows) using the same chromophore as in e, ii.  753 
(f,g) In vivo, color fundus photographs of pig eyes from the GLP pig study taken 6 weeks 754 
after transplantation surgery. (f) The picture shows an eye that has been implanted with a 755 
‘patch’ consisting of an hESC-derived RPE monolayer on a human-vitronectin coated 756 
polyester membrane. The patch is seen as a consistent and evenly pigmented cellular 757 
covering over the entire area. (g) Uncoated patch with no cells, which has been implanted 758 
as a control.  759 
(h) Cresyl violet stain of pig retina at 6 weeks post-transplantation with a patch of RPE 760 
implanted into the subretinal space. INL, inner nuclear layer; ONL, outer nuclear layer.  761 
(i) Cresyl violet stain of pig retina at 6 weeks post-transplantation with a patch without cells 762 
implanted into the subretinal space. GCL, ganglion cell layer; INL, inner nuclear layer. Note 763 
the absence of the ONL.  764 
(j) Unstained pig retina 6 weeks post-transplantation with a patch of RPE cells which are 765 
pigmented (arrows highlight the position of the polyester membrane).  766 
(k) Serial section from the same eye stained with anti-human TRA-1-85 indicates that the 767 





Figure 4. Case 1: Pre- and post-operative imaging of the cell patch with structural and 771 
functional outcomes at 12 months following surgery. 772 
 773 
(a, i) Pre-operative color fundus photograph demonstrating the extensive sub-RPE and 774 
submacular hemorrhage extending under the fovea secondary to wet AMD. (a, ii) Spectral 775 
domain OCT (Spectralis, Heidelberg) showing pre-operative section with inset showing the 776 
position of the slice. (b, i) 12 months’ postoperative color fundus photograph showing the 777 
patch covered with pigmented cells throughout. The test also shows microperimetry results 778 
with two areas of demonstrated sensitivity (Nidek microperimetry) labeled x and y. The 779 
circles represent the extent of the visual stimulus demonstrating that it falls completely 780 
within the transplanted area. Inset § shows a magnified detail of the patch area with the 781 
levels of sensitivity shown by microperimetry in decibels. Inset * shows a close up of the 782 
fixation with the Nidek microperimeter fixation outcome superimposed. (b, ii) Spectral 783 
domain OCT (Spectralis, Heidelberg) showing post-operative section with inset showing 784 
the position of the slice. The patch is shown in position with thinned retina over the area of 785 
the patch but an intact ellipsoid layer. (c, i,ii) Spectral domain OCT sections through x and 786 
y, respectively. The area on the section corresponding to x and y is indicated with a bar.  787 
The long red arrow in c, i and c, ii indicates the ellipsoid layer. The thin and bold green 788 
arrows in c, i and c, ii indicate the synthetic membrane and the hESC-RPE, respectively. 789 
(d, i) Images from the Rtx1 AO fundus camera. (Inset) Color fundus photo with 790 
superimposed area of AO imaging.  The dotted yellow circle corresponds to the area of 791 
positive microperimetry sensitivity marked x throughout this figure. (d, i) Magnified image of 792 
the area indicated by the dotted yellow line in g, i showing bright dots corresponding to 793 
cone photoreceptors based on their size, inter-photoreceptor distance and organization 794 
(blue arrows). (d, ii) AO image taken from a normal patient at the same point of the retina 795 
as in g, ii for comparison.  (e, i) Early-phase fundus fluorescein angiogram (FFA) showing 796 
early choroidal perfusion in the area of the patch and specifically the two points of 797 
demonstrated sensitivity x and y. The dark areas over the transplanted patch, at the nasal 798 
end of the patch and the superior border, represent areas of native RPE over and under 799 
the patch, masking emission rather than absent choroidal perfusion. (e, ii) Late-phase FFA 800 
confirming choroidal perfusion and no leakage under the patch. (e, iii) SLO 801 
autofluorescence over the patch, including in areas x and y, showing dim but visible 802 
autofluorescence.  803 
 804 
Figure 5 Case 2: Pre- and post-operative imaging of the cell patch with structural and 805 




(a, i)  Preoperative color fundus photograph of the extensive sub-RPE and submacular 808 
hemorrhage extending under the fovea, secondary to wet AMD. (a, ii) Spectral domain 809 
OCT (Spectralis, Heidelberg) showing pre-operative section with inset showing the position 810 
of the slice. (b, i) 12 months post-operative color fundus photograph showing the patch 811 
covered with pigmented cells throughout. There is extensive epiretinal fibrosis associated 812 
with the extent of the disease and a retinal detachment that had been successfully 813 
reattached. The test also shows microperimetry (Nidek microperimetry) results with two 814 
areas of demonstrated sensitivity labeled x and y. Inset § shows a magnified detail of the 815 
patch area with the levels of sensitivity shown by microperimetry in decibels. Inset * shows 816 
a close-up of the fixation with the Nidek microperimeter fixation outcome superimposed. 817 
The circles represent the extent of the visual stimulus demonstrating that it falls completely 818 
within the transplant area. (b, ii) Spectral domain OCT (Spectralis, Heidelberg) showing 819 
post-operative section with inset showing the position of the slice. (c, i,ii) Spectral Domain 820 
OCT cuts through area x and y, respectively, as indicated. The detail shows the Spectral 821 
Domain OCT sections through x and y, respectively. The area on the section 822 
corresponding to x and y is indicated with a bar representing the area. The long red arrows 823 
indicate the ellipsoid layer. The thin and bold green arrows indicate the synthetic 824 
membrane and the hESC-RPE respectively. (d, i) Images from the Rtx AO fundus camera. 825 
Inset - color fundus photo with superimposed area of AO imaging. The magnified image of 826 
the area indicated shows bright dots corresponding to cone photoreceptors based on their 827 
size, inter-photoreceptor distance and organization. (d, ii) An Rtx AO fundus camera image 828 
taken from a normal patient at the same point of the retina as in d, i for comparison.  (e, i)  829 
An early phase Fundus fluorescein angiogram (FFA) showing early choroidal perfusion in 830 
the area of the patch and particularly the two points of demonstrated sensitivity x and y. 831 
The dark areas temporal and superior to the transplanted patch likely represent areas of 832 
choriocapillaris loss associated with the primary pathology and surgery. (e, ii) Late phase 833 
FFA confirming choroidal perfusion and no leakage under the patch. (e, iii) SLO 834 
autofluorescence image over the patch including areas x and y demonstrating 835 




Figure 6. 838 
 839 
a. A sequence of colour photographs of the transplanted patch in case 1 at 4, 24, and 52 840 
weeks. The sequence shows the centrifugal expansion of the pigmented areas around the 841 
patch and the stability of pigmented areas on the patch.  It also shows the regression of the 842 
host RPE on the patch, with the original margin indicated by the dotted line.  b. A sequence 843 
of colour photographs of the transplanted patch in case 2 at 4, 24, and 52 weeks. The 844 
sequence shows the centrifugal expansion of the pigmented areas around the patch and 845 
relatively stable areas of pigmentation on the patch. The expansion of pigmented areas in 846 




Figure 7. 851 
 852 
a. Best Corrected Visual Acuity (BCVA) over 12 months for patient 1.  b Reading speed 853 
over 12 months for patient 1. c. BCVA over 12 months for patient 2. d. Reading speed over 854 








Online Methods. 861 
 862 
Ethics statement 863 
 864 
All animal (mouse and pig) procedures were conducted in accordance with the provisions 865 
of the United Kingdom Animals Scientific Procedures Act (ASPA) 1986. The animal 866 
experimentation under the ASPA is overseen by the Home Office, UK government, in 867 
England.  868 
 869 
The mouse teratoma studies were carried out by the Independent Contract Research 870 
(CRO) Organization Huntington Life Sciences (HLS), now Envigo (Alconbury/Huntingdon, 871 
Cambridgeshire, UK). (HLS Animal Project - Licence number PCD 70/8702). 872 
 873 
The pig surgery was carried out under GLP conditions at the Northwick Park animal 874 
experimental surgery facility (Northwick Park and St Mark’s Hospital, Harrow, Middlesex, 875 
UK). Pigs were cared for in an independent GLP registered facility including throughout the 876 
6-month’s follow-up period. The animal reporting including organ sampling was carried out 877 
independently by HLS.  878 
 879 
Clinical trial 880 
Pfizer Inc. sponsored and was the sole funding source of the clinical trial. Two subjects out 881 
of a planned 10 were enrolled before Pfizer suspended funding for strategic commercial 882 
reasons unrelated to this trial. The cells for transplantation were prepared to the state of 883 
confluent RPE at Roslin Cells Ltd (Edinburgh, United Kingdom,) before transport to 884 
London. The preparation and cutting of the patch was completed at Cells for Sight (Institute 885 
of Ophthalmology, Bath St, London, UK). 886 
  887 
Approval was granted from the U.K. Medicines and Health Products Regulatory Authority 888 
(MHRA), the Gene Therapy Advisory Committee (GTAC), the Moorfields Research 889 
Governance Committee and the London - West London & GTAC Research Ethics 890 
Committee. The study complied with Good Clinical Practice guidelines according to the 891 
European Clinical Trials Directive (Directive 2001 EU/20/EC), the Declaration of Helsinki 892 
and has an independent External Data Monitoring Committee (E-DMC). The data 893 
monitoring committee had three representatives who were retinal surgeons withtwo having 894 
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specialty expertise in ocular oncology and the third in ocular immunology. Informed 895 
consent was obtained from each patient. The study compliance with protocol was reviewed 896 
regularly, and none of the recorded protocol deviations had an impact on subject safety or 897 
study integrity  898 
 899 
Reporting Summary 900 
The Nature Biotechnology Reporting Summary has been completed and submitted with 901 
this article 902 
 903 
Statistics 904 
The only statistical analysis reported was for the phagocytosis study (Figure 2d). Data 905 
shown are mean ± s.e.m., n = 3 biologically independent cell cultures in each group. As the 906 
n is less than 10, individual data points are indicated. Analysis was by two-tailed Student’s 907 
t-test with P = 0.0000103075196107. This was a single experiment with no replication. 908 
 909 
Preparation of hESC-RPE (GMP conditions and facility). 910 
The original cell source, the SHEF1 hESC (NIBSC - UK Stem Cell Bank - 911 
http://www.nibsc.org/ukstemcellbank) line was expanded according to GMP guidelines at 912 
the Stem Cell Derivation Facility, Centre for Stem Cell Biology (CSCB), University of 913 
Sheffield35. The SHEF 1 and 1.3 cell lines were authenticated by A Short-Term Repeat 914 
Analysis fingerprint, which was performed by University of Wisconsin Hospital and Clinics. 915 
The analysis showed an identical STR genotype profile across 8 human STR loci for both 916 
SHEF-1 and SHEF-1.3. The SHEF-1.3 cell line was derived from the expanded SHEF1 917 
hESC cells under the same GMP conditions at the same facility. The passage and 918 
expansion of SHEF-1.3 hESCs was carried out in recombinant human vitronectin (VTN-N) 919 
(Life technologies)–coated culture vessels. Medium was removed from cultures and hESCs 920 
were washed with PBS-/-, incubated with EDTA (Sigma) until the cell colonies begin to 921 
detach. Cells were resuspended in Essential 8 (E8) medium (Life Technologies) and 922 
seeded onto VTN-N-coated culture vessels. hESC were replenished with E8 medium daily, 923 
and passaged every 3–4 d depending on visual observations of colony morphology and 924 
size.  925 
 926 
hESC differentiation to RPE was carried out in flasks coated with plasma-derived 927 
vitronectin (Amsbio). Sets underwent regular media replenishment with E8 medium for up 928 
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to 14 d until hESC colonies were approximately 80 to 100% confluent and then transitioned 929 
to TLP medium consisting of 389ml of Knockout DMEM, 1 ml of 2-Mercaptoethanol, 5ml of 930 
NEAA, 100 ml of Knockout serum and 5 ml of L-glutamine per 500 mL. 931 
(Invitrogen – LifeTechnologies (Thermo Fisher Scientific). Cells were maintained on a twice-932 
weekly media replenishment regimen. RPE cells appear in culture as distinct pigmented 933 
foci, visible to the naked eye, which continue to expand in diameter and can be maintained 934 
in this culture system for up to 22 weeks.  935 
 936 
RPE foci were manually isolated using sterile microblades (Interfocus) and collected in TLP 937 
medium. Pooled foci were washed with PBS-/- and incubated at 37 ± 2 °C with Accutase 938 
(Sigma) until a cell suspension is observed. The suspension was then passed through a 939 
70µm cell strainer (Corning), washed in TLP medium and counted. The cells were plated 940 
on CELLstart- coated (Life Technologies) 48-well plates at 4.8x104 cells/well. Cells were 941 
maintained on a twice-weekly media replenishment regimen of TLP medium until they 942 
formed a confluent, pigmented cell sheet with cobblestone morphology, generally for a 943 
minimum of 5 weeks.  944 
 945 
To ensure safety and purity of the RPE, it was essential to exclude the possibility of 946 
undifferentiated hESCs being administered to a patient. In situ hybridization was used to 947 
assess hESC impurity. Samples of differentiated cells were prepared as a monolayer on 948 
microscope slides. Specific oligo probes against LIN28A mRNA were used to evaluate the 949 
presence of hESC in the RPE population. LIN28A stained cells were identified using a 950 
nuclear stain. If any LIN28A positive cells were detected, the RPE batch would be rejected. 951 
Differentiated RPE were further assessed using immunocytochemistry against the 952 
melanosome-specific protein PMEL17 (Dako), an RPE cellular marker. PMEL17 positively 953 
stained cells were counted and expressed as a percentage of total cells. Upon testing of 954 
cells on representative cell patches, the RPE purity ranged from 99.8 to 100% on positive 955 
staining of PMEL17 and no LIN28A positive cells were detected. 956 
 957 
RPE cells were assessed using a light microscope for pigmentation, cobblestone 958 
morphology, health and signs of contamination and processed further only if they passed 959 
this visual check. Media was removed, cells were washed with PBS-/-, and incubated at 960 
37+/-2ºC with Accutase for 1–2 h until a cell suspension was observed. The suspension 961 
was passed through a 70µm cell strainer, washed in TLP medium and then counted. Cells 962 
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were subsequently seeded (1.16x105 cells/well) into custom manufactured transwells, with 963 
polyester membranes coated in plasma-derived human vitronectin. The membrane was 964 
10µm thick polyethylene terephthalate (PET), with a 0.4µm pore size at a density of 1x108 965 
pores/cm2 (Sterlitech, Kent, Washington, USA). TLP medium was added to the outer well 966 
containing the insert, and the plate then incubated at 37±2°C. The RPE cells were 967 
maintained with twice weekly TLP media replenishment until required for drug product 968 
manufacture.  969 
 970 
On the day of surgery, the transwell was removed from the culture plate and placed directly 971 
onto the cutting device. The patch is cut from the membrane and is then placed into the 972 
storage solution (0.9% sodium chloride) within the storage container that is then sealed. 973 
(Figure 1a.) The patch is assessed visually through the clear lid of the storage container for 974 
integrity, pigmented cell coverage and viability. The patch was transported out of the GMP 975 
facility and transferred to the operating theatre.  976 
 977 
Patch cell count. 978 
The theoretical cell count on each patch was calculated using an observed cell diameter of 979 
14um and this gives approximately 100,000 cells per patch. To complement this, two 980 
patches from preclinical production batches had the cells dissociated and counted and 981 
gave counts of 110,000 and 120,000 cells total (i.e. a cell diameter of approximately 12-982 
13um).  The theoretical cell count of 100,000 was within the confidence intervals from 983 
these two counts, and so was selected. 984 
 985 
Immunocytochemistry.  986 
Immunostaining was performed as described previously16. Briefly, cells were fixed in cold 987 
4% paraformaldehyde (PFA) in 0.1M phosphate buffer and then blocked and incubated 988 
with an appropriate combination of the following primary antibodies: TRA-1-60 (Life 989 
Technologies); Ki67 (VectorLabs); CRALBP (Thermo Scientific); PMEL17 (Dako); MERTK 990 
(Abcam); ZO-1 (Life Technologies); OTX2 (Millipore); Bestrophin (Millipore) and PEDF 991 
(Millipore). They were then incubated in the appropriate secondary antibodies including 992 
AlexaFluor 647 conjugated donkey anti-mouse Ig-G (Life Technologies), 594 conjugated 993 
donkey anti-rabbit Ig-G (Life Technologies) and Dylight 488 conjugated donkey anti-mouse 994 




Transmission electron microscopy (TEM) RPE cells immobilized on a membrane were 997 
fixed in Karnovsky’s fixative and prepared for TEM as described previously16. 998 
  999 
PEDF assay on spent media was completed using a developmental ELISA (Meso Scale 1000 
Discovery Platform S600, Mesoscale, USA) according to manufacturer’s instructions. 1001 
 1002 
Phagocytosis assay method 1003 
This was based on a previously described method 36. Purification of photoreceptor outer 1004 
segments (POS) was performed as described previously 37. The POS were labeled as 1005 
described previously38. The labeled POS were seeded onto hESC-RPE monolayer patches 1006 
grown on plasma-derived human vitronectin at 1 x 107 POS/ml. In one condition the cells 1007 
were pre-incubated with 1:50 anti MERTK antibody (ab52968, Abcam) to block 1008 
phagocytosis for one hour. The cells were incubated at 37°C in 5% CO2 for 6 hours. The 1009 
samples were fixed and stained as described previously38. To quantify phagocytosis, 3 1010 
distinct areas per patch of hESC-RPE or hESC-RPE with blocker (MERTK antibody) (n=3) 1011 
were imaged blind on the Zeiss 710 confocal. The total number of internalized fluorescent 1012 
POS were counted in a 135μm x 135μm area, using the orthogonal view function. 1013 
 1014 
Preclinical animal safety studies 1015 
 1016 
Mouse teratoma studies. 1017 
The cells tested were undifferentiated SHEF-1.3 pluripotent hESCs (hereafter ‘hESCs’), 1018 
and SHEF-1.3 hESC-derived RPE (‘hESC-RPE’). The cells were grown at a Pfizer facility 1019 
before transfer to HLS. They were injected into the eyes of NIH III Immune-Deficient Mice 1020 
(strain Crl:NIH-Lyst bgFoxn1nuBtk xid, 6-7 weeks old; Charles River, UK) at HLS. The 1021 
injections were carried out by Antony Vugler & Ahmed Ahmadoo from University College 1022 
London (UCL). Histological and pathological analyses were carried out by HLS, who 1023 
provided a report on the study. 1024 
 1025 
 1026 
The second study was completed as there were fewer tumors in female animals in the first 1027 
study. It was concluded that this was most likely linked to a decline in cell suspension 1028 
quality for dosing of the females, rather than an actual sex difference. The second study, 1029 
focused on female animals. In addition, we studied the relative rate of teratoma formation 1030 
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following subretinal, subcutaneous (SC) or IM injection of undifferentiated hESCs in female 1031 
NIH-III mice. In the second study five males were also dosed with undifferentiated hESCs 1032 
subretinally. 1033 
 1034 
In the third study, under GLP conditions, NIH III mice were administered suspensions of 1035 
hESC-RPE cells or suspensions of undifferentiated hESCs as a positive tumorigenic 1036 
control, with all injections being delivered subretinal. Other controls carried out in all the 1037 
mouse teratoma studies are listed in the tables below. Animals were followed for up to 26 1038 
weeks, allowing for the assessment of tumors associated with the administration of the test 1039 
cells, prior to the animals having an excessive burden of spontaneous tumors. The 1040 
numbers of animals injected, the site and sex are listed in the following table. 1041 
 1042 
 1043 
Mouse teratoma studies 1044 
 1045 
First study: 2-Month Pilot Study of the Teratoma Formation Potential of hESCs in NIH III 1046 
Immune-Deficient Mice  1047 
  1048 
Test condition     *Injected Number / sex animals 1049 
1. Untreated Control       5/sex  (10 total) 1050 
2. DMEM Control – Subretinal    5/sex  (10 total) 1051 
3. hESCs at 45,000 M/44,000 F cells – Subretinal  15/sex  (30 total) 1052 
4. hESCs at 88,000 M/68,000 F cells – Subretinal  15/sex  (30 total) 1053 
5. Vehicle – IM       5/sex  (10 total) 1054 
6. hESCs at 88,000 M / 68,000 F cells – IM   5/sex (10 total) 1055 
 1056 
 1057 
Second Study:  2-Month Pilot Study of the Teratoma Formation Potential of SHEF1-Cells in 1058 
Female NIH III Immune-Deficient Mice 1059 
 1060 
Test condition     *Injected Number / sex animals 1061 
1. DMEM – Subretinal    5F  (5 total) 1062 
2. hESCs at 35,600 cells – Subretinal  5/M  (20 total) 1063 
       15/F 1064 
3. Matrigel – IM     5 F  (5 total) 1065 
4. HESCS at 35,500 cells – IM   10F  (10 total) 1066 
5. hESCs at 822,500 cells – IM   10F (10 total) 1067 
6. Matrigel – SC     5F  (5 total) 1068 
7. hESCs at 35,500 cells – SC   8F  (8 total) 1069 
8. hESCs at 822,500 cells – SC   12F  (12 total) 1070 
 1071 
Third Study (GLP conditions) Teratoma Formation Potential of hESC-RPE in NIH III Immune 1072 




Test condition     Injected Number / sex animals 1075 
1. KO DMEM Control      10/sex  (20 total) 1076 
2. mTeSR™  Control      10/sex  (20 Total) 1077 
3. hESC-RPE at 5340 cells* in KO DMEM  20/sex  (40 Total) 1078 
4. hESC-RPE at 60,400 cells* in KO DMEM 20/sex  (40 Total) 1079 
5. hESCs at 4510 cells§ in mTeSR    19 M/20 F  (29 Total) 1080 
6. hESCs at 42,800 cells§ in mTeSR   20 M/19 F  (29 Total) 1081 
 1082 
DMEM = Dulbecco’s Modified Eagle Medium; KO DMEM = Knockout DMEM; 1083 
IM = Intramuscular; SC = Subcutaneous. M = Male; F = Female;  1084 
RPE = Retinal Pigment Epithelium;  1085 
§ Represents the average number of cells administered to the group. 1086 
 1087 
Necropsy and histology. 1088 
At the end of the study animals were subject to a detailed necropsy and macroscopic 1089 
examinations were performed on all treated and control animals.  The following tissues 1090 
were processed for histological examination: abnormal masses, epididymides, eyes, heart, 1091 
kidneys, liver, lymph nodes (mesenteric, submandibular), optic nerves, ovaries, spleen, 1092 
sternum with bone marrow, testes. Tissues and organs were collected and fixed in 10% 1093 
neutral buffer except the eyes and optic nerves which were fixed in Davidson’s fluid. 1094 
Following histological processing and review any teratomas or abnormal masses were 1095 
subject to immunohistochemistry (IHC) (anti-human mitochondrial marker staining), using a 1096 
validated method to confirm whether these were of human or mouse origin. 1097 
 1098 
Pig transplantation feasibility studies. 1099 
The analysis of the biodistribution data in pig tissues (looking for the evidence of human 1100 
cells in different organs) was done using qPCR by the independent CRO Aros (Aarhus, 1101 
Denmark) with reports provided.   1102 
 1103 
Surgical safety, successful delivery of the RPE patch, local and systemic biodistribution 1104 
and toxicology were examined in these studies. The pig was selected since the size of the 1105 
pig eye allowed for the administration of the intended full-size patch and would allow the 1106 
study of surgical feasibility, biocompatibility and biodistribution. All pig studies described 1107 
were performed by the same surgeon who operated in the two cases described in the initial 1108 
clinical trial. In the second pig study the same clinical surgical technique was used as in the 1109 
human trial. 1110 
 1111 
First pig study. 1112 
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In this study, SHEF1-derived RPE cells were seeded onto a BD Matrigel (BD Biosciences, 1113 
Erembodegem, Belgium)-coated polyester membrane and manually implanted as a 1x3 1114 
mm membrane into the subretinal space of pig eyes via 20G pars plana vitrectomy, bleb 1115 
detachment with retinotomy followed by air tamponade. Twenty animals underwent surgery 1116 
and 12 of these received hESC-derived-RPE cells on the membrane, 2 at each time point, 1117 
with the remainder receiving a membrane without cells, 1 at each time point except 6 1118 
weeks where there were 3 animals. Six of the animals received immunosuppression with 1119 
oral cyclosporine (650 mg for up to 2 weeks following surgery). Animals were observed, 1120 
euthanized and enucleated at 2 hours, 2 d, 1, 2, 4, and 6 weeks. Eyes were examined by 1121 
light and electron microscopy.  1122 
 1123 
Second pig study. 1124 
Safety/Biodistribution Study of therapeutic patch in Pigs for 26 Weeks 1125 
Following Surgical (Intraocular), subretinal Implantation 1126 
 1127 
1. Control (vitronectin coated polyester membrane only)  5/sex (Total 10) 1128 
2. PF-05206388 1 graft (100,000 cells plus vitronectin   5/sex (Total 10) 1129 
 coated polyester membrane) 1130 
 1131 
Toxicity. 1132 
The feasibility of the surgical procedure and the general safety of PF-05206388 was 1133 
assessed in studies performed in the Large White/Landrace hybrid pigs (in all cases).  1134 
 1135 
In the GLP pig study, a group of 5 male and 5 female pigs were administered a patch at a 1136 
dose of 1 graft in the left eye (approximately 100,000 SHEF-1.3 derived RPE cells on a 1137 
vitronectin coated polyester membrane) and observed for 26 weeks (6 months). A similarly 1138 
constituted control group of 5 male and 5 female animals received the vitronectin coated 1139 
polyester membrane only. The membrane with or without cells was placed into the 1140 
subretinal space in all 20 pigs using the same tool and surgical technique as in the clinical 1141 
trial. Animals received Prednisolone (1 mg/kg) orally 7 d before surgery, which continued 1142 
for 14 d post operatively, intravitreal 4 mg Triamcinolone Acetonide (TCA) during the 1143 
surgery, Sub tenon TCA 40mg at the end of surgery, and Carprofen (4 mg/kg) was given 1144 
orally postoperative on day 2 of the study. Eye drops of 0.1% dexamethasone, 0.5% 1145 
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hypromellose and 0.35% neomycin were administered to all the pigs 4 times per day for 17 1146 
d post-surgery. 1147 
 1148 
Systemic distribution of cells. 1149 
The distribution of the hESC-RPE cells was evaluated as part of the pivotal 26-week 1150 
toxicity study in pigs. The biodistribution was evaluated using qPCR techniques and the 1151 
human cell markers huGAPD, huPEDF, HSSRY, huPOU5F1, and huOTX1/2 and the pig 1152 
marker, pigACTB. A total of 60 samples from each animal (5/sex/group) that included the 1153 
following: adrenal, bone marrow (rib and femur), brain (7 sections), heart (5 sections), 1154 
kidneys (5 sections), liver (6 sections), lungs (5 sections), lymph nodes (4 nodes, total 8 1155 
sections), optic nerve (left and right, proximal and distal to eye), spleen (5 sections), 1156 
thymus (3 sections) were evaluated. To avoid a high number of false positives, positives in 1157 
at least 2 individual human markers in the same sample were required. There were no 1158 
animals that received the matrix only that had an increase in amplifying human transcripts.  1159 
 1160 
Cell spiking studies.  1161 
 1162 
The effect of deliberately spiking hESCs into RPE was assessed.  Different proportions (0, 1163 
1, 10, 20, 50 or 100%) of hESCs were mixed with dissociated RPE foci (P0 cells), seeded 1164 
into 96 well plates at 38,000 cells/cm2 and cultured for 6 weeks (P1 cells) using standard 1165 
RPE culture conditions.  Feeder-free hESC were used for spiking to eliminate counting 1166 
inaccuracies due to the presence of fibroblast feeder cells.  Plates were fixed and stained 1167 
for TRA-1-60 or PMEL17 and the corresponding no primary antibody controls (n=4 plates, 1168 
1 well/plate stained with each antibody/control). A single cell suspension of hESCs was 1169 
also seeded onto Matrigel in mTeSR1 media with ROCK inhibitor 2 d before fixing as a 1170 
positive control for TRA-1-60 staining.   1171 
 1172 
Flow cytometry. 1173 
Cells were washed with PBS and treated with Accutase to produce a single cell 1174 
suspension, before pelleting and resuspended in 3% BSA/PBS to 1 million/ml. 100,000 1175 
cells per sample were incubated on ice for 20 min with IgM-PE isotype control (eBioscience 1176 
12-4752- 82), TRA-1-60-PE (eBioscience 12-8863-82, PE) or Tra-1-81-PE (eBioscience 1177 
12-8883-80) at 1/20 dilution. For propidium iodide (PI) staining, 100μl 1.5μM PI (Sigma) 1178 
was added to 100μl cells and incubated for 10-15min on ice. Samples were pelleted and 1179 
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resuspended in 150μl PBS alone (for PI stained samples) or PBS containing 50nM 1180 
TOPRO3 (Invitrogen), a dead cell stain, for IgM and TRA-1-60 samples. Samples were run 1181 
on the Accuri Cflow flow cytometer. Debris, TOPRO3 positive dead cells (except 1182 
when deliberately analyzing dead populations) and cell doublets were excluded from the 1183 
analysis.  1184 
 1185 
Immunostaining. 1186 
For live PI staining, 100μl 1.5μM PI (Sigma) in PBS was added to wells containing 100μl 1187 
cells/media. After 10min PI/media was aspirated and replaced with 100μl 1:10000 1188 
HOESCHT in PBS. Plates were imaged live on the Image Express Micro platform 1189 
(Molecular Devices Corporation). For immunostaining, cells were fixed with 4% PFA for 1190 
20min, washed with PBS-/- and blocked with 5% NDS in 0.3% triton-X/PBS for 1 hour. 1191 
Primary antibody in 1% NDS/TX/PBS was then applied for a further hour at room 1192 
temperature. The antibodies used were TRA-1-60 at 1:100 (Abcam 16288, mouse), 1193 
PMEL17 at 1:25 (DAKO HMB45, mouse monoclonal) or 1:500 Ki67 (Vector K451, rabbit). 1194 
Wells were washed three times with 1% NDS/TX/PBS and secondary antibody, at 1:200 1195 
in 1% NDS/TX/PBS applied for 1 hour at room temperature. For TRA-1-60 Jackson anti-1196 
mouse IgM (715-485-020) was used, for PMEL17 Invitrogen Alexa Fluor 488 anti-mouse 1197 
and for Ki67 Alexa Fluor 488 antirabbit was used. Wells were then washed three times 1198 
with PBS-/- and 1:10,000 HOESCHT applied. These were imaged on the Image Express 1199 
Micro platform (Molecular Devices Corporation); automated image analysis was performed 1200 
using MetaExpress software. The best settings for this analysis were determined both by 1201 
visual observation of the plates and by choosing. 1202 
 1203 
The introducer tool. 1204 
The patch delivery tool was custom designed and manufactured with the aim of providing 1205 
protected delivery of the therapeutic patch until its placement into the subretinal space. The 1206 
device consists of a handle containing a mechanism to advance a flexible rod that passes 1207 
from the wheel, through the shaft and to the tip where the rod physically pushes the patch 1208 
out of the tip of the device (supplementary figure 1.).  The rod is advanced by virtue of the 1209 
wheel on the handle that the surgeon rolls forward to advance the patch out of the device 1210 





Clinical trial. 1214 
Subjects in the trial underwent extensive screening and follow-up investigations including 1215 
(i) blood sampling for: Hematology: Hemoglobin, Hematocrit, RBC, Platelet, WBC count 1216 
and differential; Chemistry: Urea, Creatinine, Glucose, Calcium, Sodium, Potassium, 1217 
Chloride, Total CO2, AST, ALT, Total Bilirubin, ALP, Uric acid, Albumin, Total protein; HIV, 1218 
HepB and HepC testing; (ii) Urinalysis for pH, Glucose, Protein, Blood, Ketones, Nitrites, 1219 
Leukocyte esterase, microscopy and a drug screen. 1220 
 1221 
A physical examination, including head, ears, eyes, nose, mouth, skin, heart and lung, 1222 
lymph nodes, gastrointestinal, musculoskeletal, and neurological systems, blood pressure, 1223 
pulse rate and Electrocardiograms, was also performed.  1224 
 1225 
Primary endpoints. 1226 
1. Incidence and severity of adverse events. 1227 
2. Change from baseline in Early Treatment Diabetic Retinopathy (ETDRS) best corrected 1228 
visual acuity (BCVA) - Proportion of subjects with an improvement of 15 letters or more 1229 
at Week 24. 1230 
 1231 
Inclusion criteria. 1232 
1. Male and /or post-menopausal (defined as at least 12 consecutive months with no 1233 
menses without an alternative medical cause) female subjects aged 60 years or above. 1234 
2. Diagnosis of wet age-related macular degeneration (AMD) with evidence of good 1235 
foveal fixation in the study eye plus at least one of: 1236 
• History of sudden decline in vision within 6 weeks of the time of surgery (Day 1) 1237 
associated with evidence of an RPE tear extending under the fovea. 1238 
• History of sudden decline in vision within 6 weeks of the time of surgery (Day 1) 1239 
associated with a sub macular hemorrhage with greatest dimension of 6 disc 1240 
diameters. 1241 
• Evidence of failure to respond to anti-VEGF treatments as defined by declining 1242 
vision ≥25 ETDRS letters within 20 weeks prior to surgery (Day 1) despite at least 3 1243 
injections of anti-VEGF. 1244 
3. BCVA value recorded of 6/36 Snellen equivalent or worse in the study eye during or 1245 
within 14 d of the screening period. 1246 




5. Subjects who are willing and able to comply with all scheduled visits, treatment plan, 1249 
laboratory tests, and other study procedures. 1250 
 1251 
Exclusion criteria. 1252 
1.  Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, 1253 
gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic disease 1254 
(including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at 1255 
time of dosing) or other severe acute or chronic medical or surgical condition or 1256 
laboratory abnormality that may increase the risk associated with study participation or 1257 
investigational product administration or may interfere with the interpretation of study 1258 
results and, in the judgment of the investigator, would make the subject inappropriate for 1259 
entry into this study. 1260 
2. Pregnant females; breastfeeding females; and females of childbearing potential 1261 
3. Positive urine drug screen for illicit drugs or drugs of abuse. 1262 
4. History of regular alcohol consumption exceeding 14 units/week for females or 21 1263 
units/week for males within 6 months of screening. 1264 
5. Treatment with an investigational drug within 30 d (or as determined by the local 1265 
requirement, whichever is longer) or 5 half-lives preceding the first dose of study 1266 
medication. 1267 
6. Blood donation of >1 pint (500 mL) within 56 d prior to dosing. 1268 
7. Subject unwilling or unable to comply with the Lifestyle Guidelines described in this 1269 
protocol. 1270 
8. Contraindication to general anesthesia (as determined by the attending anesthetist). 1271 
9. Previous significant retinal disease in the study eye (other than AMD), as determined by 1272 
the investigator. 1273 
10. Current or previous significant other ocular disease in the study eye, as determined by 1274 
the investigator. 1275 
11. Any ocular disease in the study eye that might alter the ocular media and reduce the 1276 
posterior segment view, as determined by the investigator. 1277 
12. Any previous retinal surgery in the study eye. 1278 
13. Contraindication to prednisolone, triamcinolone, cefuroxime or fluocinolone acetonide 1279 
(specifically increased intra-ocular pressure or glaucoma). 1280 
14. History of sensitivity to heparin or heparin-induced thrombocytopenia. 1281 
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15. Use of anti-VEGF therapy (e.g., Lucentis) within 7 d of surgery in the study eye. 1282 
16. Participation in another ongoing interventional clinical study. 1283 
17. Limited use of non-prescription medications that are not believed to affect subject 1284 
safety or the overall results of the study may be permitted on a case-by-case basis 1285 
following approval by the sponsor. 1286 
18. Subjects who are investigational site staff members or relatives of those site staff 1287 
members or subjects who are Pfizer employees directly involved in the conduct of the 1288 
study. 1289 
 1290 
Visit schedule. 1291 
Subjects attended the hospital on an out-patient basis for up to three d during the 1292 
screening interval (Day -21 to Day 0). Eligible subjects attended the hospital on an 1293 
out-patient basis the day before surgery (Day 0) for pre-surgery assessments. Insertion of 1294 
PF-05206388 (the hESC-RPE patch) occurred the following day (Day 1). Subjects were 1295 
discharged from the hospital the day after surgery (Day 2). There was a second operative 1296 
procedure performed at the Week 10 visit (Visit 9) whereby the silicone oil, which was 1297 
inserted at the time of PF-05206388 insertion, was removed from the eye. Subjects with 1298 
significant cataracts noted at screening were permitted to have the cataracts removed at 1299 
the time of this second surgical procedure. For the first procedure, subjects received up to 1300 
1 mg/kg oral prednisolone (up to 60 mg maximum) daily commenced 2-4 d pre-operatively 1301 
and continued for at least 2 weeks followed by a tailing off over at least 1 further week. 1302 
Subjects also received single doses of sub-Tenon triamcinolone acetonide 40 mg and sub 1303 
conjunctival cefuroxime (250 mg in 1 mL) after patch insertion. For the second procedure, 1304 
subjects received up to 1 mg/kg oral prednisolone (up to 60 mg maximum) daily 1305 
commenced 7 d pre-operatively and continued for at least 2 weeks followed by a tailing off 1306 
over at least 1 further week. Subjects also received an intravitreal implant of fluocinolone 1307 
acetonide either 0.19 or 0.59 mg as an anti-inflammatory agent and sub conjunctival 1308 
cefuroxime (250 mg in 1 mL) post-surgery.  1309 
 1310 
The first surgical procedure was carried out on Day 1, subjects were discharged from 1311 
hospital on Day 2 and attended for post-surgical evaluations at Week 1, Week 2, Week 4, 1312 





Surgical procedures. 1316 
Transplantation operation: patients underwent standard general anesthesia. Routine sterile 1317 
povidone-iodine 5% preparation of the eye with and draping of the face was completed. 1318 
The eyelids were separated with a disposable Barraquer speculum. For case 1 a cataract 1319 
was removed and a single focus, one-piece, acrylic lens for emmetopria was inserted, at 1320 
the time of the transplant surgery, while subject 2 was already pseudophakic. A 270 degree 1321 
peritomy with a standard 23-gauge infusion and 2 further ports were inserted. Pars plana 1322 
vitrectomy with induction of PVD when not present was completed with subsequent 360 1323 
degree Argon laser. A macular retinal detachment was created with a 38 gauge de Juan 1324 
dual bore cannula, the retinotomy was enlarged with microscissors and the subretinal 1325 
space irrigated to remove all blood and fibrin. The temporal port was widened for 1326 
introduction of the delivery device and insertion of the patch into the sub retinal space. The 1327 
macular was re-attached with heavy liquid and the retinotomy lasered. A routine search of 1328 
the retinal periphery was completed in both cases with no iatrogenic breaks detected. 1329 
Air/fluid followed by air/silicone oil exchange was carried out. The ports were sutured and 1330 
the infusion removed. Sub-Tenon triamcinolone acetonide 40mg and subconjunctival 1331 
cefuroxime (250 mg/1 ml) were injected followed by sub-Tenon (0.5% bupivacaine).  1332 
 1333 
Removal of Silicone Oil:  silicone oil was removed under sub-Tenon local anaesthesia. A 1334 
23-gauge infusion was inserted in the infero-temporal quadrant and a second port created 1335 
to aspirate the oil. The retinal periphery was examined for breaks. The ports were closed 1336 
and subconjunctival antibiotics were given. For subject 2 an operation to reattach a 1337 
detached retina, consisting of epiretinal membrane peeling, inferior 180 degree retinectomy 1338 
and laser, was carried out before the oil removal. 1339 
 1340 
Ocular tests and examinations. 1341 
 1342 
Biomicroscopic evaluation and intra-ocular pressure measurement were carried out using a 1343 
Haag-Streit 900 slit-lamp (Koeniz, Switzerland) and Goldmann applanation tonometer. 1344 
 1345 
Fundus photography, angiography. 1346 
Colour, red-free fundus photographs and standard fluorescein and indocyanine green 1347 
angiography (50°) were acquired through dilated pupils using the Topcon TRC Retinal 1348 




Spectral-domain OCT scan and cSLO reflectance imaging. 1351 
Volume scan and EDI volume scan, 20°x20°, 49 sections, ART 12, High Speed scans and 1352 
30°, 55° short-wave reflectance autofluorescence images were acquired through dilated 1353 
pupils using the Spectralis OCT (Heidelberg Engineering GmbH, Heidelberg, Germany) 1354 
 1355 
Adaptive optics. 1356 
AO images were acquired through dilated pupils using the ImagineEyes Camera (Orsey, 1357 
France). Alignment and data collection was repeated for several retinal locations. 1358 
For calculation of cellular density, a freely available image-processing program (ImageJ, 1359 
National Institutes of Health, Bethesda, Maryland) was used to manually identify the cones 1360 
in each subject's retinal image.  1361 
 1362 
Pattern ERG, full-field ERG and EOG. 1363 
Pattern ERG, full-field ERG and EOG were performed according the ISCEV standards. 1364 
Dark-adapted ERGs were recorded to flashes of 0.01 and 10.0 cd.s.m-2 (DA0.01; DA10.0); 1365 
light adapted responses were recorded to flashes of 3.0 cd.s.m-2 (30Hz and 2Hz). 1366 
 1367 
Automated perimetry. 1368 
Visual fields were assessed using Humphrey Field Analyzer (Carl Zeiss Meditec, AG, Jena, 1369 
Germany). Central 24-2 Threshold tests were performed using Goldmann III white stimulus 1370 
at background luminance of 31.5ASB, in SITA-FAST strategy.  1371 
 1372 
Microperimetry. 1373 
A customized rectangular grid of 9-23 loci covering the area of the RPE patch was used in 1374 
Nidek MP1 Microperimeter (NAVIS software 1.7.2, Nidec Technologies, Padova, Italy). 1375 
Stimuli were set to Goldmann III-V size, white color, 200ms duration and 0-20dB intensity 1376 
with background luminance at 1.27cd/m2. A single red-cross 2-3° target was used for 30 1377 
seconds fixation stability assessment. A 4-2 staircase strategy was employed to assess the 1378 
retinal sensitivity through dilated pupils after 15min dark adaptation.  1379 
 1380 
ETDRS/logmar best corrected visual acuity (BCVA) - distant and near, 1381 
including contrast sensitivity (CS). 1382 
Refracted BCVA was tested by Independent Trained optometrists using the Early 1383 
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Treatment of Diabetic Retinopathy Study (ETDRS) charts and CS the Pelli-Robson chart at 1384 
1 meter. 1385 
 1386 
Minnesota reading test (MNREAD). 1387 
The MNREAD sentences were used to assess the visual processing capabilities and eye-1388 
movement control required for normal text reading. Each sentence contains 60 characters 1389 
(including a space between each word and at the end of each line) printed as three lines 1390 
with even left and right margins. The vocabulary used in the sentences is selected from 1391 
high-frequency words that appear in second- and third-grade reading material. The charts 1392 
contain sentences with 19 different print sizes. From the recommended viewing distance of 1393 
40 cm (16 in.) the print size ranges from +1.3 to -0.5 logMAR (Snellen equivalents: 20/400-1394 
20/6). 1395 
 1396 
B-mode orbital ultrasound. 1397 
Ultrasound scans were acquired through sterile gel, using the ACUSON SequoiaTM512 1398 
system (Siemens Healthcare, USA) 1399 
 1400 
Ocular oncologist review. 1401 
Specialist Ocular oncologists reviewed the patients with biomicroscopic evaluation and 1402 
review of images from the ultrasound, fundus photography and fundus angiography. 1403 
 1404 
Data validation. 1405 
This manuscript is generated from an unlocked database and includes some data that 1406 
Pfizer is not responsible for validating/storing.  1407 
 1408 
Data availability statement. 1409 
The majority of data generated or analysed during this study are included in this published 1410 
article and its supplementary information. Any further data concerning the current study are 1411 
available from the corresponding author on reasonable request. There are no accession 1412 
codes, unique identifiers, or web links to publicly available datasets related to this study.  1413 
 1414 
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